HSIC

Company Overview: Henry Schein, Inc. is a global healthcare solutions provider with a market cap of $8.5 billion, primarily serving dental and medical professionals, and has experienced a decline in stock value despite reporting a revenue increase in its fourth-quarter results.

Market Performance: The company's shares have underperformed compared to the Nasdaq Composite, with a 16.3% drop from its 52-week high, while analysts maintain a "Moderate Buy" rating with a price target suggesting potential growth.

Henry Schein's Support for Special Olympics: Henry Schein, Inc. is donating essential health care products to support the Healthy Athletes screenings at the Special Olympics World Winter Games in Turin 2025, continuing their partnership since 2018 to provide free health screenings and education for athletes with intellectual and developmental disabilities.

Impact of Healthy Athletes Program: The Healthy Athletes initiative has delivered over two million free health screenings and trained more than 300,000 healthcare professionals, enhancing access to quality healthcare for individuals with intellectual and developmental disabilities both during and beyond Special Olympics events.

Utah's Water Fluoridation Ban: Utah's legislature has passed a bill to ban water fluoridation, which the Governor is expected to sign, potentially boosting dental demand in the state over time.

Impact on Dental Industry: Analysts suggest that this ban could lead to increased growth in dental consumables and are monitoring similar legislative efforts in other states like North Dakota, Tennessee, and Montana.

Recognition of Ethical Standards: Henry Schein, Inc. has been recognized as one of the 2025 World’s Most Ethical Companies by Ethisphere for the 14th consecutive year, highlighting its commitment to ethical business practices and corporate citizenship efforts.

Corporate Citizenship Initiatives: The company’s global program, Henry Schein Cares, focuses on improving healthcare access, supporting disaster relief, and fostering a culture of engagement among employees, while also contributing over $22.6 million in products and cash to various organizations in 2024.

Market Concerns: Fund manager Nathan Rawlins is receiving inquiries from clients about economic uncertainty and the potential market environment changes due to tariff issues.

Investment Focus Shift: As riskier market segments decline, there may be increased investor interest in the American Century Mid-Cap Value Fund, which Rawlins co-manages, particularly as big technology stocks lose favor by early 2025.

Upcoming Meeting: A meeting will be held on March 10 at 11 am, hosted by Oppenheimer.

Investment Insights: TipRanks offers tools to discover top-rated stocks and maximize investment portfolios, including a Stock Screener for filtering and analyzing opportunities.

Put Contract Strategy: Investors can sell a put contract at a $70.00 strike price for a premium of $3.00, effectively lowering their cost basis to $67.00 per share, which is attractive compared to the current market price of $71.72. There is a 64% chance that the contract may expire worthless, yielding a potential return of 4.29%.

Call Contract Strategy: Purchasing shares at $71.72 and selling a call contract at a $75.00 strike price for a premium of $4.90 could yield an 11.41% total return if exercised by January 2026, with a 47% chance of the contract expiring worthless, providing a 6.83% additional return.

Company Presentation: Henry Schein, Inc. will present at the Leerink Global Healthcare Conference on March 11, 2025, in Miami, with a live webcast available for listeners.

About Henry Schein: The company is a leading provider of healthcare solutions for dental and medical practitioners, operating globally with over 25,000 employees and reporting sales of $12.7 billion in 2024.

Market Performance: The S&P 500 closed slightly up while the Dow Jones fell, with notable gains in tech stocks ahead of Nvidia's earnings report. Positive corporate news from companies like Axon Enterprise and Intuit contributed to market support, despite some economic disappointments and hawkish comments from the Atlanta Fed President.

Economic Indicators: Upcoming economic reports are expected to show modest growth, with a projected increase in Q4 GDP and slight easing in inflation measures. However, new home sales dropped significantly, and mortgage applications declined, indicating potential challenges in the housing market.

Analyst Rating Changes: Several Wall Street analysts have adjusted their price targets and ratings for various companies, including cuts for Henry Schein and ZipRecruiter, while Prothena Corporation and CrowdStrike saw increases in their targets.

Stock Performance: The article highlights the closing prices of several stocks on Tuesday, with notable movements such as ZoomInfo Technologies experiencing a significant increase, while ZipRecruiter faced a substantial decline.

Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts and exclusive stories to enhance their market strategies.

Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from accurate stock market intelligence.

Market Performance: Major U.S. stock indexes are up today, driven by gains in chip stocks and positive corporate earnings reports, with notable increases from Super Micro Computer, Axon Enterprise, and Intuit.

Economic Developments: House Republicans passed a budget blueprint that could lead to significant tax cuts and increased debt limits, while bond yields rose; however, disappointing economic data on new home sales and mortgage applications weighed on market sentiment.

Rising Star Award Announcement: Henry Schein Medical is accepting nominations for the 2025 Rising Star Award, which honors emerging athletic trainers with 1-5 years of experience. Nominations are open until March 5, 2025, and finalists will be selected by a panel of experts.

Award Details and Recognition: The winner of the Rising Star Award will be announced on March 27, 2025, and will receive a MARC PRO handheld muscle stimulator and a Medi Kit™ MULE roller bag filled with supplies. Last year's award was given to Aline Valiengo from Coconut Creek High School.

Rising Star Award Announcement: Henry Schein Medical is accepting nominations for the 2025 Rising Star Award, which honors emerging athletic trainers with 1 to 5 years of experience in sports medicine. Nominations are open until March 5, 2025, and public voting will occur from March 19 to March 25, 2025.

Recognition of Athletic Trainers: The award aims to spotlight the talent and dedication of athletic trainers, with past winners showcasing significant contributions to the profession. The winner will receive a MARC PRO handheld muscle stimulator and a Medi Kit™ MULE roller bag filled with supplies.

Analyst Ratings: Stifel Nicolaus analyst Jonathan Block has maintained a Buy rating on Henry Schein (HSIC) with a price target of $80.00, while Bank of America also issued a Buy rating, contrasting with Leerink Partners' Hold rating.

Company Performance: Henry Schein's market cap is $9.68B with a P/E ratio of 31.79, and the company reported Q4 adjusted EPS of $1.19, slightly below the consensus of $1.21.

Fourth Quarter Financial Results: Henry Schein Inc. reported a fourth-quarter adjusted EPS of $1.19, an 80.3% increase year-over-year but below the consensus estimate of $1.21. Sales reached $3.19 billion, a 5.8% increase, also missing expectations.

Future Outlook and Strategy: The company forecasts 2025 adjusted EPS between $4.80-$4.94, slightly below Wall Street's consensus of $5.01, citing stable but weak market demand. They have restructured into three segments to enhance growth and profitability as part of their BOLD+1 Strategic Plan.

Company Overview: Henry Schein, Inc., a global distributor of healthcare products based in New York, has seen its stock performance lag behind the broader market over the past year but has gained momentum in 2025, with shares rising 11.6% year-to-date following a significant investment from KKR & Co. Inc.

Analyst Ratings and Future Outlook: Analysts have a consensus rating of "Moderate Buy" for HSIC, with expectations of a 5.3% EPS growth for FY2024; however, uncertainties regarding tariffs and market conditions remain a concern, despite a mean price target suggesting a potential upside.

Earnings Report Expectations: HENRY SCHEIN ($HSIC) is set to release its quarterly earnings on February 25th, with analysts predicting revenue of approximately $3.37 billion and earnings of $1.24 per share.

Insider Trading Activity: In the past six months, HENRY SCHEIN insiders have conducted two stock sales with no purchases, while institutional investors have shown mixed activity, with 225 adding shares and 320 reducing their positions.

Henry Schein Inc Analysis: Henry Schein Inc (HSIC) is rated highest among 22 guru strategies using the Shareholder Yield Investor model, scoring 60% based on its fundamentals and valuation, indicating moderate interest in the stock.

Meb Faber's Investment Strategy: Meb Faber, founder of Cambria Investments, emphasizes shareholder yield by focusing on companies that return cash to shareholders through dividends, buybacks, and debt paydown, which forms the basis of his investment strategy and related ETF.

Wells Fargo Coverage Initiation: On February 14, 2025, Wells Fargo began coverage of Henry Schein with an Equal-Weight recommendation, projecting a 1.97% price increase based on an average target of $77.52/share.

Institutional Ownership Trends: There has been a decrease in institutional ownership of Henry Schein, with notable reductions from major shareholders like Jpmorgan Chase and American Century Companies, while the overall fund sentiment remains bullish as indicated by a put/call ratio of 0.86.